Table 2.

Genant-modified Sharp Score: median change from baseline at 12 months in the AIM trial

	Median change from baseline (25th, 75th percentile)
	Abatacept–MTX (n=424)	Placebo–MTX (n=214)	p (abatacept vs placebo)
Erosion score	0.00 (0.00, 1.02)	0.27 (0.00, 1.27)	0.029
Joint space narrowing	0.00 (0.00, 0.49)	0.00 (0.00, 0.97)	0.009
Total score	0.25 (0.00, 1.78)	0.53 (0.00, 2.54)	0.012

Abbreviations: AIM, Abatacept in patients with an inadequate response to methotrexate; MTX, methotrexate.